Cal, since Labour Day, DMX has traded over 57 million shares.
Given the short position you posted, and the possibility that residual PIPE investors may still be playing offshore games with Dimethaid, one wonders what the future holds, in terms of trading.
Still, it's nice to see the price stabilize. Long time since we've seen it.
Maybe once The Bandidos get flushed from the stock, TA will become a reliable tool again. How many TA predictions have gone wrong because of PIPE financing, and shorting?
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
What do you suppose the sequence of events will be from here?
Dr. Kuhne's interim financing has left a few month's breathing room to get Dimethaid's affairs in order. The recent revitalization of the Solvay agreement may be the first step in Dimethaid's rehabilitation.
(1) - The next step may be negotiation of new deals for Pennsaid and Penecure, and perhaps the market hasn't priced this properly. CaptainKlutz made a good SH post on Pennsaid:
stockhouse.ca
to which the Penecure possibility was added:
stockhouse.ca
(2) - The addition of US $20 million plus to the kitty (not an unreasonable case) would pay off all debt, divest Varennes, and leave Dimethaid in good shape.
(3) - At that point, it might be proper to announce new trials for WF10, including cancer and HCV, already mentioned by the company.
(4) - THEN would be the time to finance, IMO. The financing could probably be done in excess of $1.
Pure speculation, admitted.
But the numbers aren't unreasonable. A lot would depend on the interest of potential suitors. Maybe there's less interest than we hope, but I continue to believe that the potential in Dimethaid is greater than commonly understood.
Beauty is in the eye of the beholder - and the market's "eye" on Dimethaid has become a little jaundiced. Perhaps, too jaundiced.
Everyone's been so badly burned by past events.
New management has been recognized as a breath of fresh air. Optimism still seems quite cautious.
Jim |
